Product Accepted Twice On PRIME Marks A First For EMA
Executive Summary
Vertex and CRISPR can now get access to the advantages afforded by the European Medicines Agency’s priority medicines scheme for both of the indications they are targeting with their investigational gene therapy, CTX001.